Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Gritstone bio, Inc. (GRTS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates -- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE in first-line metastatic microsatellite-stable colorectal cancer ; preliminary efficacy data expected in 1Q 2024 -- -- Gritstone partnering with Friends of Cancer Research on Friends’ ctDNA for Monitoring Treatment Response Project, a collaborative research initiative to inform use of ctDNA change as surrogate for survival benefit -- -- Publication in Nature Communications of interim CORAL-BOOST results highlights the potential of Gritstone’s self-amplifying mRNA candidates to serve as next-generation vaccine against SARS-CoV-2 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $122.3 million as ..."
05/11/2023 8-K Quarterly results
Docs: "Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE to date; 71 of 80 patients enrolled as of May 10, 2023-- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, CALIF."
03/09/2023 8-K Quarterly results
Docs: "Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates -- Preliminary data from GRANITE Phase 2/3 study remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 -- -- Clinical evidence building for differentiation of self-amplifying mRNA as a potential next-gen mRNA platform in infectious disease -- -- Cash, cash equivalents, marketable securities, and restricted cash of $185.2 million as of December 31, 2022 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, CALIF."
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy